CEO Converts Preferred Stock to Common Stock Ahead of IPO
EIKN is trading near its 52-week low of $13.3 (2.3% above the low) on light trading volume (0.3× avg).
Summary
Eikon Therapeutics' CEO and Director, Roger M. Perlmutter, converted over $3.8 million worth of preferred stock into common stock immediately prior to the company's IPO.
Key Events · Ownership and Investor Activity · EIKN
-
CEO Stock Conversion
Roger M. Perlmutter, CEO and Director, converted preferred stock into 284,857 shares of common stock.
-
Pre-IPO Alignment
The conversion, valued at $3,876,904, occurred immediately prior to the company's IPO, aligning the CEO's interests with common shareholders.
-
Significant Holdings Change
This transaction represents a substantial change in the CEO's direct common stock holdings post-IPO, contributing to a broader pattern of insider accumulation.
Analysis · EIKN · Life Sciences
This Form 4 filing details a significant change in holdings for Eikon Therapeutics' CEO and Director, Roger M. Perlmutter. On February 6, 2026, Mr. Perlmutter converted preferred stock into common stock, a transaction valued at over $3.8 million. This conversion occurred immediately prior to the company's initial public offering, a standard procedure for pre-IPO investors that aligns the CEO's equity interests directly with those of common shareholders. This move solidifies the CEO's stake in the company's public equity, following a series of insider purchases and conversions around the IPO date.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 30.2% of the 1644 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.49%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, EIKN was trading at $13.61 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $787.2M. The 52-week trading range was $13.30 to $17.40. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.